Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.

NCT07154238 · Enrolling by invitation

Last updated 2026-05-28

This study describes the characteristics and treatment experiences of adults with obesity who are using injectable semaglutide for weight management across multiple countries.

Status Enrolling by invitation Only people invited by the researchers can join.

Type Observational

Participants 2,546 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-09 · est. completion 2026-09

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT07154238 ↗

Description as written by the study sponsor.

The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.

Treatments tested

No treatment given Other

No treatment given

Main thing measured	Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07154238 ↗